BioNTech SE (NASDAQ:BNTX) shares rose ~8% in premarket trading on Friday after the company and partner Duality Biologics reported positive Phase 3 trial results for their breast cancer treatment.
The drug, tested in China, showed it was more effective than an existing therapy at slowing disease progression in patients with advanced HER2-positive breast cancer.
This is the first positive Phase 3 data readout achieved in BioNTech’s and DualityBio’s strategic collaboration initiated in April 2023, and the collaboration aims to accelerate the development of differentiated ADC therapeutics for solid tumors.
Additional global Phase 3 DYNASTY-Breast02 trial evaluating trastuzumab pamirtecan in patients with metastatic HER2-low breast cancer is ongoing and on track, the companies said.
